Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Gonadotropin-releasing Hormone Analog

Review the clinical trials studying gonadotropin-releasing hormone analog on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 47

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Status: Active
Location: 1128 locations
Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Status: Active
Location: 754 locations
Two Studies for Patients with Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a Higher Gene Risk Score, The Guidance Trial
Status: Active
Location: 554 locations
Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Status: Active
Location: 325 locations
Treating Prostate Cancer That Has Come Back after Surgery with Apalutamide and Targeted Radiation Based on PET Imaging, INDICATE Trial
Status: Active
Location: 296 locations
Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer, the ADEPT study
Status: Active
Location: 41 locations
Testing the Anti-cancer Drug Darolutamide in Patients with Testosterone-Driven Salivary Gland Cancers
Status: Active
Location: 27 locations
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Status: Active
Location: 16 locations
Studying the Effects of Removing Adjuvant Chemotherapy for the Treatment of Estrogen Receptor-Positive, HER2-Negative Breast Cancer in Patients with a Low-Genomic Risk, SELECT Trial
Status: Active
Location: 12 locations
Relugolix or Leuprolide for Treatment in Men with Prostate Cancer
Status: Active
Location: 8 locations
Combination of Avutometinib, Defactinib, and Letrozole for the Treatment of Low-Grade Serous Ovarian Cancer
Status: Active
Location: 8 locations
Standard of Care Treatment (Hormonal Therapy and Stereotactic Ablative Radiation Therapy) Alone or in Combination with Niraparib, Abiraterone and Prednisone for the Treatment of Metastatic Prostate Cancer, KNIGHTS Trial
Status: Active
Location: 7 locations
2141-V11 in Combination with Standard Therapy for the Treatment of Prostate Cancer Prior to Surgery
Status: Active
Location: 7 locations
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Status: Active
Location: 7 locations
Talazoparib with Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer, TRIPLE-PRO Trial
Status: Active
Location: 5 locations
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
Status: Active
Location: 4 locations
Evaluation of Response to Abiraterone Acetate, Prednisone, and Androgen Deprivation Therapy by Race or Ethnicity in Patients with Metastatic Prostate Cancer
Status: Active
Location: 3 locations
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Status: Active
Location: 6 locations
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Location: 3 locations
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for the Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
Status: Active
Location: 3 locations
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Status: Active
Location: 4 locations
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Status: Active
Location: 2 locations
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Status: Active
Location: 4 locations
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Status: Active
Location: 5 locations
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
Status: Active
Location: 2 locations